Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: The FINESSE-ANGIO (Facilitated Intervention with Enhanced Reperfusion Speed to Stop EventsAngiographic) study

JACC: Cardiovascular Interventions

Volumn 3, Issue 12, 2010, Pages 1284-1291

  Prati, Francesco ^a   Petronio, Sonia ^c   Van Boven, Ad J ^f   Tendera, Michal ^g   De Luca, Leonardo ^b   De Belder, Mark A ⁱ   Galassi, Alfredo R ^d   Imola, Fabrizio ^a   Montalescot, Gilles ^j   Peruga, Jan Z ^h   Barnathan, Elliot S ^k   Ellis, Stephen ^l   Savonitto, Stefano ^e  

^a MOLINETTE HOSPITAL   (Italy)

^b EUROPEAN HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f MEDICAL CENTER LEEUWARDEN   (Netherlands)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h MEDICAL UNIVERSITY OF LODZ   (Poland)

ⁱ JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k CENTOCOR INC   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

abciximab; facilitated percutaneous coronary intervention; fibrinolytic therapy; ST segment elevation myocardial infarction

Indexed keywords

ABCIXIMAB; PLACEBO; RETEPLASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ASSESSMENT TOOL; COMPARATIVE STUDY; CORONARY ARTERY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; THROMBOLYSIS IN MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT PLANNING; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; FIBRINOLYTIC AGENTS; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; STATISTICS, NONPARAMETRIC; VASCULAR PATENCY;

EID: 78651401825     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.08.023     Document Type: Article

References (41)

1. The GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction N Engl J Med 329 1993 1615 1622
2. GISSI Investigators Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) Lancet 1 1986 397 402
3. L.K. Newby, W.R. Rutsch, R.M. Califf GUSTO-1 Investigators Time from symptom onset to treatment and outcomes after thrombolytic therapy J Am Coll Cardiol 27 1996 1646 1655
4. B.R. Brodie, T.D. Stuckey, C. Hansen, and D. Muncy Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction Am J Cardiol 85 2000 13 18
5. A.L. Liem, A.W. van 't Hof, J.C. Hoorntje, M.J. de Boer, H. Suryapranata, and F. Zijlstra Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty J Am Coll Cardiol 32 1998 629 633 (Pubitemid 28435245)
6. C.P. Cannon, C.M. Gibson, and C.T. Lambrew Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction JAMA 283 2000 2941 2947
7. M.T. Roe, E.M. Ohman, and A.C. Maas Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion J Am Coll Cardiol 37 2001 9 18
8. E.M. Antman, R.P. Giugliano, C.M. Gibson TIMI 14 Investigators Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial Circulation 99 1999 2720 2732
9. L.F. van den Merkhof, F. Zijlstra, and H. Olsson Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study J Am Coll Cardiol 33 1999 1528 1532
10. G. Montalescot, P. Barragan, O. Wittenberg ADMIRAL Investigators Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction N Engl J Med 344 2001 1895 1903 (Pubitemid 32553358)
11. F.J. Neumann, R. Blasini, and C. Schmitt Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction Circulation 98 1998 2695 2701
12. C.P. Cannon Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction J Am Coll Cardiol 34 1999 1395 1402
13. E. Antman, J. de Lemos, and E. Braunwald Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction Eur Heart J 3 Suppl A 2001 A8 A13
14. J.A. de Lemos, E.M. Antman, and C.M. Gibson Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction Observations from the TIMI 14 trial Circulation 101 2000 239 243
15. S.G. Ellis, P. Armstrong, A. Betriu FINESSE Investigators Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial Am Heart J 147 2004 648
16. S.G. Ellis, M. Tendera, M.A. de Belder FINESSE Investigators Facilitated PCI in patients with ST-elevation myocardial infarction N Engl J Med 358 2008 2205 2217
17. A. Manginas, P. Gatzov, C. Chasikidis, V. Voudris, G. Pavlides, and D.V. Cokkinos Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method Am J Cardiol 83 1999 1562 1565
18. U. Zeymer, R. Zahn, and R. Schiele Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized Integrilin in Acute Myocardial Infarction (INTAMI) pilot trial Eur Heart J 26 2005 1971 1977
19. M. Gyongyosi, H. Domanovits, W. Benzer ReoPro-BRIDGING Study Group Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusionresults of the Austrian multi-centre randomized ReoPro-BRIDGING Study Eur Heart J 25 2004 2125 2133
20. M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R.P. Dabizzi Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial) J Am Coll Cardiol 49 2007 1517 1524
21. A.W. van't Hof, N. Ernst, M.J. de Boer On-TIME Study Group Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial Eur Heart J 25 2004 837 846
22. C.M. Gibson, A.J. Kirtane, S.A. Murphy TIMI Study Group Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial Am Heart J 152 2006 668 675
23. D.P. Lee, N.A. Herity, B.L. Hiatt TIGER-PA Investigators Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial Circulation 107 2003 1497 1501
24. G. De Luca, H. Suryapranata, and G.W. Stone Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials JAMA 293 2005 1759 1765
25. D. Antoniucci, A. Migliorini, and G. Parodi Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone Circulation 109 2004 1704 1706
26. G. Montalescot, D. Antoniucci, and A. Kastrati Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up Eur Heart J 28 2007 443 449
27. G. De Luca, C.M. Gibson, and F. Bellandi Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis Heart 94 2008 1548 1558
28. B.S. Coller Potential non-glycoprotein IIb/IIIa effects of abciximab Am Heart J 138 1999 S1 S5
29. M. Schwarz, T. Nordt, C. Bode, and K. Peter The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2) Thromb Res 107 2002 121 128
30. P. Ortolani, A. Marzocchi, and C. Marrozzini Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network Eur Heart J 30 2009 33 43
31. T. Rakowski, Z. Siudak, and A. Dziewierz Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile Results from EUROTRANSFER registry Am Heart J 158 2009 569 575
32. B.J. Gersh, G.W. Stone, H.D. White, and D.R. Holmes Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 293 2005 979 986
33. G.W. Stone, D. Cox, and E. Garcia Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials Circulation 104 2001 636 641
34. A.M. Ross, K.S. Coyne, J.S. Reiner PACT Investigators A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial Plasminogen-activator Angioplasty Compatibility Trial J Am Coll Cardiol 34 1999 1954 1962
35. The ASSENT-4 PCI Investigators Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial Lancet 367 2006 569 578
36. S.G. Ellis, M. Tendera, M.A. de Belder FINESSE Investigators 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial J Am Coll Cardiol Intv 2 2009 909 916
37. H.C. Herrmann, J. Lu, B.R. Brodie FINESSE Investigators Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals J Am Coll Cardiol Intv 2 2009 917 924
38. B.R. Brodie, T.D. Stuckey, and T.C. Wall Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction J Am Coll Cardiol 32 1998 1312 1319
39. P. Widimsky, L. Groch, M. Zelizko, M. Aschermann, F. Bednar, and H. Suryapranata Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory The PRAGUE study Eur Heart J 21 2000 823 831
40. J. Mehilli, A. Kastrati, S. Schulz BRAVE-3 Investigators Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial Circulation 119 2009 1933 1940
41. E. Boersma, R.A. Harrington, D.J. Moliterno, H. White, and M.L. Simoons Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes Lancet 360 2002 342 343